Search results
Showing 1 to 15 of 15 results for itp
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.
Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)
Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)
Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.
Eltrombopag for treating chronic immune thrombocytopenia (TA293)
Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune thrombocytopenia in adults.
A timeline showing where in the NICE evaluation process companies will be charged.
Charging procedure for NICE technology appraisal and highly specialised technologies evaluations
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)
Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]
In development Reference number: GID-HST10063 Expected publication date: TBC
analysing observational data including, but not limited to, the existing UK ITP Registry, which collects data on the long-term outcomes...
Engage at the optimal time for your technology appraisal, to achieve NICE guidance at the same time as marketing authorisation.
Routine antenatal anti-D prophylaxis for women who are rhesus D negative (TA156)
Evidence-based recommendations on routine anti-D prophylaxis for women who are rhesus D negative.
View recommendations for TA156Show all sections
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA205)
This guidance has been updated and replaced by NICE technology appraisal guidance 293.
This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.
View recommendations for NG235Show all sections
Sections for NG235
- Overview
- Recommendations
- Recommendations for research
- Rationale and impact
- Context
- Appendix A: Adverse outcomes for different places of birth
- Appendix B: Outcomes for different places of birth – by BMI at booking
- Appendix C: Outcomes for intravenous remifentanil patient-controlled analgesia (PCA) compared with intramuscular pethidine